These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 7852189)

  • 1. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
    Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
    Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
    Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
    Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
    Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
    Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
    Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
    Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
    Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
    Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
    Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
    Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
    Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
    Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
    Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
    Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
    Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
    Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
    Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.